Commercial Space Company Risk / Opportunity Ranking

Thesis: Recent very large funding, high stated valuation, and evidence of expanding sovereign SAR demand support a durable multi-quarter scaling thesis.

Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon.

Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims.

Thesis: SpaceX has the strongest evidence-set-backed long-horizon opportunity because it secured multiple large, recent government awards that deepen its role as a core military and civil space infrastructure provider, with contract scope spanning surveillance, communications backbone, and additional NASA crew missions.

Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon.

Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here.

Thesis: Apex has the strongest opportunity case in this screen because multiple dated June 2026 sources say it raised over $200 million at a $2.3 billion valuation specifically to scale high-rate satellite bus production for proliferated constellations, and a separate dated June 2026 article says Northrop partnered with Apex on space-based interceptors for Golden Dome. Together, these indicate fresh capital, scaling intent, and positioning with government/defense demand vectors over a 1 year+ horizon.

Why now: Why now is strong because the key financing evidence is dated June 5, 2026 and the Northrop partnership article is dated June 1, 2026, making both recent within the 90-day recent evidence window and relevant to a 1 year+ scaling thesis. The June 5 financing event is later than the April 16 capacity/context article and therefore better reflects current business state.

Caveats: Most available evidence is neutral fact or supporting article context, not explicit positive events. Same-day repeated articles around the fundraise are not independent proof beyond corroboration. Some context sources are company-issued or article-level summaries, which are weaker than direct events.

Thesis: AST SpaceMobile has strong long-horizon opportunity because it achieved a critical regulatory milestone for a 248-satellite direct-to-device constellation and continues to show ecosystem buildout through operator partnerships and stated constellation scale targets.

Why now: The key timing event is the FCC authorization dated April 21, 2026/April 22, 2026 granting authority for up to 248 satellites and direct-to-device service, a milestone that can unlock U.S. commercial and government use cases over a 1 year+ horizon. Later-dated company-site context on June 23, 2026 also says AST has nearly 60 operator partners and targets direct broadband to standard smartphones.

Caveats: Much of the evidence is company, press-release, or article-context based rather than independent hard performance metrics. The reviewed sources cites a target of 45 to 60 BlueBird satellites by end-2026 in article summary context, but this is not available as a direct structured fact here.

Thesis: BlackSky has the strongest recent opportunity evidence in the screen: a multi-year sole-source $99 million U.S. government IDIQ tied to next-generation Earth observation and space domain awareness development, plus a separate $25 million multi-year assured contract with a major international defense customer. Together these indicate current government demand, product validation, and longer-horizon backlog/ARR support.

Why now: The why-now is supported by two dated recent wins inside the recent evidence window: on March 31, 2026 BlackSky said it received a multi-year sole-source $99 million U.S. government IDIQ and initial $2 million funding for advanced large-aperture payload design; on April 22, 2026 it announced a competitive $25 million multi-year assured contract with a major international defense customer and said it had four Gen-3 satellites on orbit and was rapidly deploying Gen-3 capacity while driving up backlog and annual recurring revenue.

Caveats: The $99 million figure is an IDIQ ceiling, not fully funded revenue at announcement; only an initial $2 million was specifically disclosed. Some corroboration repeats the same underlying announcement and should not be treated as independent evidence

Thesis: Boeing has the strongest opportunity evidence in this screen because the reviewed sources includes recent company-linked fact evidence that it won a $2 billion U.S. Space Force contract to build two next-generation MUOS communications satellites. The award covers design, development, production, testing, and on-orbit support for a critical military SATCOM network, with launches no earlier than 2031 and 2032 and constellation support through 2035. That is a material, durable space/defense win aligned with the 1 year+ horizon

Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance

Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031.

Thesis: Capella Space has the strongest opportunity profile in this screen because the reviewed sources includes a dated, company-specific contract fact showing it won a roughly $49 million SDA contract to build two satellites for a military communications demonstration, adding to evidence that it operates advanced SAR satellite capabilities and serves government and strategic customers.

Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure.

Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and

Thesis: Impulse Space has the strongest opportunity setup in this screen based on recent, company-linked financing evidence that it raised $500 million in Series D funding to scale production of orbital transfer vehicles, with article context also indicating expansion to support growing commercial and government demand. For a 1 year+ horizon, that capital base can support production scale-up and program execution.

Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis.

Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here.

Thesis: Katalyst Space Technologies has a strong opportunity profile because the reviewed sources show recent evidence of both mission relevance and financing: a NASA Phase III SBIR contract to develop a rescue concept for the Neil Gehrels Swift Observatory and a later June 23, 2026 report that it raised $12 million to develop its NEXUS robotic spacecraft and expand satellite servicing.

Why now: Why now is strong because the latest dated evidence on June 23, 2026 adds new capital after the May 29, 2026 NASA-related mission context, supporting a 1 year+ thesis that the company is moving from concept credibility toward funded development in on-orbit servicing.

Caveats: Part of the positive case comes from company-issued materials and supporting article context rather than independent positive evidence. The May 29, 2026 article includes a dated source date but describes an announcement text beginning 'August 11, 2025'; chronology should therefore be read carefully, with the treated as the recency marker for this retrieved item. Citation

Thesis: Northrop Grumman has the strongest reviewed sources-supported opportunity profile in this screen due to multiple recent space-defense catalysts: inclusion in the April 8, 2026 Andromeda RG-XX awards, a June 1, 2026 partnership with Apex on Golden Dome space-based interceptors, and a June 22, 2026 $398M Space Force contract for the Enhanced Protected Tactical SATCOM Prototype. Together these support a durable 1 year+ defense-space demand thesis.

Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum.

Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events.

Thesis: Observable Space has the strongest positive setup in this screen because the reviewed sources contain dated evidence that it raised a $90 million Series A and secured a $94 million U.S. Space Force optical-systems contract, supporting capital availability, customer validation, and potential multi-quarter execution runway.

Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon

Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence.

Thesis: PLD Space has recent financing, strategic customer/investor validation, infrastructure investment, and a first commercial launch contract, all of which support a durable launch-scaling thesis over the next year-plus.

Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon.

Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material.

Thesis: Quantum Space has the clearest evidence-backed opportunity profile in this screen: within the recent evidence window it announced a SPAC merger expected to bring substantial capital and public-market access, and later won a Pentagon-funded orbital refueling spacecraft contract built on its Ranger platform. Those developments support a durable 1 year+ thesis around funding access, national-security positioning, and product relevance in on-orbit logistics.

Why now: The evidence is recent and sequenced: on June 8, 2026 Quantum Space announced its planned SPAC merger and expected Nasdaq listing under QSPC

Caveats: Most available evidence is external overlay context rather than first-party positive or negative events. Same-theme repetition across June articles is not independent confirmation. Ticker QSPC is prospective after the expected SPAC close per June 8, 2026 evidence, not confirmed as already trading under that symbol

Thesis: True Anomaly has the strongest opportunity profile in this screen because the reviewed sources contain dated, company-linked evidence that it raised $650 million in Series D financing at a $2.2 billion valuation on April 28, 2026 and was selected by the U.S. Space Force for the Space-Based Interceptor program on May 4, 2026. For a 1 year+ horizon, that combination of fresh capital plus program participation supports scaling, product development, and defense-space positioning.

Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis.

Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously.

Thesis: Anduril has a credible 1 year+ opportunity setup from recent participation in major U.S. defense-space programs and fresh financing context. Recent article context says Anduril was among companies awarded Space Force Andromeda contracts for the RG-XX satellite effort on April 8, 2026, and a later article says Anduril raised a $5B Series H round published June 19, 2026, supporting capital availability for scaling in defense-space programs.

Why now: The timing is supported by recent 2026 article context around Space Force Andromeda participation and the June 19, 2026 financing context, which together suggest active momentum over the last quarter.

Caveats: Most evidence is weak context-only article evidence, not direct positive events in the available ranking rows.

Thesis: Astroscale has the clearest 1 year+ opportunity setup in this screen: within the recent evidence window article context shows recent funding support, strategic growth financing for medium-to-long-term expansion, and a shift from demos toward repeatable commercial missions, including defense-related servicing and a 2027 inspection mission pipeline.

Why now: Recency is the main reason: on June 22, 2026 SpaceNews said Astroscale was 'working to transition from technology demonstrations to a regular series of missions, bolstered by a recent capital infusion' and saw 'repeatable business opportunities' particularly among defense customers. On May 19, 2026 financing materials said the company would raise 30.6 billion yen to secure medium-to-long-term growth funding 'in anticipation of transitioning to a phase of continuous order acquisition'. On April 6, 2026 Astroscale revealed its ISSA-J1 mission scheduled for launch in 2027.

Caveats: Most within the recent evidence window evidence is supporting article context, not structured company-specific events; reviewed sources warns supporting article context is weaker than direct event/fact evidence. Same-article repeated weak-context rows are not independent confirmation. Older 2023 and 2025 articles exist in representative articles but fall outside the 90-day recent evidence window for ranking use.

Thesis: Best opportunity profile in this screen based on multiple dated article-context items showing the company remains active in in-orbit servicing/debris removal, has financing support, is ramping toward ClearSpace-1, and is expanding into defense-adjacent partnership activity. For a 1 year+ horizon, that combination supports a credible strategic growth and market-positioning thesis.

Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation.

Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated.

Thesis: Cowboy Space has the strongest positive evidence in this screen: a large Series B financing at a substantial valuation, explicit plans to build vertically integrated rockets plus orbital data-center infrastructure, and stated hiring/buildout activity. That combination supports a durable 1 year+ strategic opportunity thesis.

Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028

Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency.

Thesis: Dawn Aerospace has the strongest opportunity evidence in this screen because a recent dated company article says it closed a $25 million Series B at a $195 million post-money valuation to accelerate global expansion of reusable space transportation. The funding is directly tied to rollout, commercial scaling in the US and Europe, and support for an expanding international customer base, which fits a 1 year+ horizon.

Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe.

Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context.

Thesis: Eutelsat has a strong long-horizon opportunity case from the reviewed sources' membership rationale stating it is supervising a 264-satellite IRIS2 element and won a €350M French defense satellite contract with sovereign LEO capacity. That combines infrastructure scale with government-backed demand.

Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration.

Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload.

Thesis: No direct negative evidence is retained in the reviewed sources for KVH Industries within the selected recent evidence window.

Why now: The membership rationale says KVH appeared as a listed player in a generic defense satellite communication market report tied to article: but the reviewed sources retains zero evidence after recent evidence window and provides no, so this is too weak for a directional thesis.

Caveats: Generic market-report mention is weaker than company-specific event evidence. The support article ID is cited in the reviewed sources rationale but no article or retained evidence row is provided.

Thesis: No material adverse evidence is available. The low risk score should be interpreted as insufficient evidence, not affirmative de-risking.

Why now: Why-now is weak because no within the recent evidence window evidence are available, so timing, financing status, and launch progress cannot be judged from the current reviewed sources.

Caveats: Membership rationale references, and, but no article details are available here. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Potential IPO/funding relevance is mentioned only in membership rationale and cannot be elevated without direct evidence.

Thesis: No direct negative evidence is available in the reviewed sources, so no risk thesis is supportable.

Why now: The reviewed sources only describes that Intuitive Machines acquired Lanteris for about $800M via article, but provides no available evidence, no business description, and no.

Caveats: Acquisition mention without business detail is insufficient for ranking direction. No post-recent evidence window evidence are available. Referenced has no in the reviewed sources.

Thesis: No direct adverse evidence is available in the reviewed sources, and the main limitation is that Leidos appears to be a defense IT contractor rather than a core commercial space operator under these cohort rules.

Why now: No surviving evidence are available after the 90-day filter despite 300 articles considered. The rationale cites: and: but no are provided in these reviewed sources.

Caveats: Membership rationale is not direct directional proof. No retained evidence after recent evidence window. Cohort fit is ambiguous because support is infrastructure/IT modernization rather than operator economics.

Thesis: The reviewed sources does not provide direct negative evidence on LeoLabs in the available recent evidence window period, so risk scoring remains low.

Why now: No dated company-specific evidence are available after filtering, so there is no strong timing signal in these reviewed sources.

Caveats: No usable evidence after recent evidence window. Membership rationale is insufficient for a high score.

Thesis: No retained adverse evidence exists in the active recent evidence window, so only a low risk score is supportable from these reviewed sources.

Why now: The only concrete company-specific article summary says Leonardo was self-funding a 20-satellite Earth-observation constellation on February 23, 2026, but that date is older than the March 29, 2026 cutoff, so recency is insufficient for a stronger current thesis.

Caveats: The cited article is outside the 90-day recent evidence window; reviewed sources reports kept_rows 0 and dropped_rows 2. No retained positive or negative evidence exist after filtering. Article-level recap context is weaker than direct event/fact evidence.

Thesis: No retained adverse evidence is shown, so a negative thesis is likewise unsupported.

Why now: Why now is weak because 8 articles were considered but zero remained after the March 29, 2026 cutoff, leaving no current catalyst or status confirmation.

Caveats: No recent evidence window-qualified evidence. Phase-2 rationale is not enough for directional conviction.

Thesis: Insufficient retained evidence within the reviewed sources to support a material adverse thesis.

Why now: There is no available post-recent evidence window evidence for this company. The reviewed sources notes two considered articles, but zero article IDs after recent evidence window and zero evidence retained, so recency-sensitive judgment is not possible.

Caveats: The reviewed sources say support used article IDs existed earlier, but no retained evidence are available after the 90-day recent evidence window cutoff of March 29, 2026. Absence of evidence is not positive or negative proof.

Thesis: There is no direct adverse evidence in the reviewed sources; the main risk is that evidence is context-only and insufficient to assess business traction or downside.

Why now: No dated or citable event evidence is available. The reviewed sources indicates provisional single-article context tied to article id: but no or summary is provided and no evidence survived recent evidence window.

Caveats: Support level is explicitly provisional_single_article_context, which is weaker than company-specific event or fact evidence. No current evidence is provided for article: preventing direct citation. Scores remain minimal due to lack of evidence, not a strong negative view.

Thesis: No material adverse evidence is available in the reviewed sources.

Why now: There is no retained post-recent evidence window evidence row in these reviewed sources despite membership rationale referencing NASA-related wins, so timing support is insufficient.

Caveats: Membership rationale is not enough for a strong thesis without cited retained evidence. Coverage after recent evidence window is effectively zero in these reviewed sources.

Thesis: There is no direct adverse evidence in the reviewed sources within the recent evidence window; risk is scored low because the reviewed sources are evidence-empty rather than because the business is de-risked.

Why now: No within the recent evidence window company-specific catalyst or business-state change is available. Coverage debug shows 0 article IDs after recent evidence window and 0 evidence after recent evidence window, with cutoff date March 29, 2026.

Caveats: Reviewed evidence references only a profile-like article via membership rationale, not available direct evidence: but no is provided in these reviewed sources. No current source-cited evidence was found in the reviewed sources.

Thesis: There is no material adverse evidence available after recent evidence filtering; the main risk is that the company's actual role and relevance cannot be established from reviewed sources evidence.

Why now: No direct catalyst or citable business-state evidence is available. The reviewed sources references article ids: and: but provides no and no retained evidence.

Caveats: The reviewed sources explicitly says the evidence is mostly thematic/stock-basket context rather than direct business description. No or quotes are provided for direct citation.

Thesis: No material adverse thesis is supportable from the retained evidence in these reviewed sources. The low risk score reflects lack of evidence, not business quality.

Why now: Why now is weak because the reviewed sources' evidence recent evidence review shows zero kept rows after the 90-day cutoff ending March 29, 2026 and coverage data shows articles after recent evidence window of 0, so recency is not established from retained evidence.

Caveats: Phase-2 membership rationale cites but no or retained evidence row is provided in these reviewed sources, so it cannot be used for factual claims. Coverage after recent evidence window is effectively empty: evidence recent evidence review cutoff_date March 29, 2026 with kept_rows 0. Scores reflect insufficient evidence, not a fundamental bearish or bullish view.

Thesis: No material adverse thesis is supportable from the retained evidence.

Why now: Why now is weak because no evidence survived the 90-day recent evidence window in the available reviewed sources; evidence recent evidence review kept_rows is 0 and coverage data articles after recent evidence window is 0.

Caveats: Phase-2 rationale is not enough for a factual claim without and retained evidence detail. No within the recent evidence window direct evidence is available. Low scores reflect absence of usable evidence.

Thesis: No retained 90-day direct negative evidence is available to support a risk thesis.

Why now: The reviewed sources show zero retained article IDs and zero evidence after recent evidence filtering, so there is no recent company-specific evidence base for a 1 year+ directional call.

Caveats: Historical membership support references article IDs, but no post-recent evidence window evidence are served here. Low scores reflect insufficient evidence, not an evaluated business conclusion.

Thesis: No material adverse evidence is available within the reviewed sources' recent evidence window.

Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Marlan Space.

Caveats: Phase-2 membership rationale references article: but the reviewed sources provide no for citation. Partnership context alone should not be treated as propagated operating evidence under the evidence standard.

Thesis: No material negative evidence is available; the main risk is lack of current reviewed sources evidence and classification as a supplier rather than a core space operator.

Why now: There is no surviving 90-day evidence to establish a current catalyst. The rationale references and: without in these reviewed sources.

Caveats: Supplier exposure alone is not enough for a strong positive thesis without direct, timely event evidence. No retained evidence after recent evidence window.

Thesis: No adverse evidence is present. Risk stays low because there is no material negative event in the reviewed sources.

Why now: Why now is weak because there are no representative articles or available evidence after recent evidence window, and the only support is the membership rationale referencing: without article summary details in the ranking fields.

Caveats: No representative article content is included for direct citation beyond membership rationale reference. No direct positive or negative evidence are available after recent evidence window. Scoring is constrained by sparse surfaced evidence.

Thesis: There is also insufficient direct adverse evidence; the main risk is simply that the reviewed sources' support is generic and not company-event-specific, preventing a meaningful thesis ranking.

Why now: No 'why now' is evidenced. The reviewed sources show zero post-recent evidence window available evidence despite a large article universe.

Caveats: Phase-2 rationale references: but no or summary is provided. Generic market-report mention is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window.

Thesis: No retained direct negative evidence is provided, so the reviewed sources does not support a material adverse thesis either.

Why now: Why now is weak because despite 72 articles considered, zero article IDs and zero evidence were retained after the March 29, 2026 cutoff, preventing any current sequencing or catalyst assessment.

Caveats: No admissible post-recent evidence window evidence. Membership review rationale is contextual only and not a directional scoring basis by itself.